[go: up one dir, main page]

NO20064866L - IRTA-5 antistoffer og deres anvendelse - Google Patents

IRTA-5 antistoffer og deres anvendelse

Info

Publication number
NO20064866L
NO20064866L NO20064866A NO20064866A NO20064866L NO 20064866 L NO20064866 L NO 20064866L NO 20064866 A NO20064866 A NO 20064866A NO 20064866 A NO20064866 A NO 20064866A NO 20064866 L NO20064866 L NO 20064866L
Authority
NO
Norway
Prior art keywords
antibodies
irta
methods
furthermore
monoclonal antibodies
Prior art date
Application number
NO20064866A
Other languages
English (en)
Inventor
Josephine M Cardarelli
Robert Graziano
Thomas Kempe
Beth Cutter
Mohan Srinivasan
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of NO20064866L publication Critical patent/NO20064866L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Sammendrag 0. nr. P60602096NO00 Det tilveiebringes isolerte, monoklonale antistoffer og særlig humane monoklonale antistoffer, som spesifikt binder til IRTA-5 med høy affinitet. Det tilveiebringes videre nukleinsyremolekyler som koder antistoffene ifølge oppfinnelsen, ekspresjonsvektorer, vertsceller og metoder for å uttrykke antistoffene ifølge oppfinnelsen. Videre tilveiebringes det immunokonjugater, bispesifikke molekyler og farmasøytiske preparater omfattende antistoffene ifølge oppfinnelsen. Videre tilveiebringes det metoder for å detektere IRTA-5, så vel som metoder for å behandle forskjellige B-cellemalignanser inkludert ikke-Hodgkin's lymfom.
NO20064866A 2004-03-29 2006-10-25 IRTA-5 antistoffer og deres anvendelse NO20064866L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55774104P 2004-03-29 2004-03-29
PCT/US2005/010265 WO2005097185A2 (en) 2004-03-29 2005-03-29 Irta-5 antibodies and their uses

Publications (1)

Publication Number Publication Date
NO20064866L true NO20064866L (no) 2006-12-22

Family

ID=35125622

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064866A NO20064866L (no) 2004-03-29 2006-10-25 IRTA-5 antistoffer og deres anvendelse

Country Status (12)

Country Link
US (2) US20050266008A1 (no)
EP (1) EP1740210A4 (no)
JP (1) JP2007530076A (no)
KR (1) KR20070036038A (no)
CN (1) CN1950107A (no)
AU (1) AU2005231348A1 (no)
CA (1) CA2561276A1 (no)
IL (1) IL178277A0 (no)
MX (1) MXPA06011201A (no)
NO (1) NO20064866L (no)
WO (1) WO2005097185A2 (no)
ZA (1) ZA200608100B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7858330B2 (en) * 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7888478B2 (en) * 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2006017759A2 (en) * 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
EP1866338B1 (en) 2005-03-23 2016-09-21 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20070166306A1 (en) * 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
ES2732278T3 (es) * 2006-09-26 2019-11-21 Genmab As Anti-CD38 más corticosteroides más un agente quimioterapéutico no corticosteroideo para el tratamiento de tumores
HRP20120759T1 (hr) * 2007-04-03 2012-10-31 Amgen Research (Munich) Gmbh Bispecifična veziva specifična između vrsta
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
CN101951946B (zh) * 2007-10-01 2014-12-10 百时美施贵宝公司 结合间皮素的人抗体及其应用
AU2010313324A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
RS59769B1 (sr) 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
WO2012153193A2 (en) 2011-05-08 2012-11-15 Legochem Biosciences, Inc. Protein-active agent conjugates and method for preparing the same
EA037084B9 (ru) * 2014-12-04 2021-08-05 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
EP3227339B1 (en) * 2014-12-05 2021-11-10 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
CA3007031A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
WO2019093342A1 (ja) * 2017-11-08 2019-05-16 協和発酵キリン株式会社 ＣＤ４０とＥｐＣＡＭに結合するバイスペシフィック抗体
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
US20190300610A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
JP7670627B2 (ja) 2019-02-18 2025-04-30 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
AU2021283564B2 (en) * 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
EP4274586A1 (en) * 2021-01-07 2023-11-15 Innovative Cellular Therapeutics Holdings, Ltd. Car cells and polyspecific binding molecules for treating solid tumor
EP4477752A1 (en) 2022-02-09 2024-12-18 National Institutes of Biomedical Innovation, Health and Nutrition Antibody or fragment thereof that binds to fcrl1
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568625T3 (es) * 1999-11-29 2016-05-03 The Trustees Of Columbia University In The City Of New York Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
US20040005561A1 (en) * 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7317087B2 (en) * 2002-03-25 2008-01-08 The Uab Research Foundation Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof

Also Published As

Publication number Publication date
CA2561276A1 (en) 2005-10-20
US20080187547A1 (en) 2008-08-07
WO2005097185A2 (en) 2005-10-20
EP1740210A4 (en) 2009-03-25
ZA200608100B (en) 2009-09-30
JP2007530076A (ja) 2007-11-01
CN1950107A (zh) 2007-04-18
EP1740210A2 (en) 2007-01-10
MXPA06011201A (es) 2008-01-28
IL178277A0 (en) 2006-12-31
AU2005231348A1 (en) 2005-10-20
WO2005097185A3 (en) 2006-04-20
US20050266008A1 (en) 2005-12-01
KR20070036038A (ko) 2007-04-02

Similar Documents

Publication Publication Date Title
NO20064866L (no) IRTA-5 antistoffer og deres anvendelse
NO20080362L (no) CD19-antistoffer og deres anvendelser
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
WO2005058815A3 (en) Ip-10 antibodies and their uses
WO2006076691A3 (en) Irta-2 antibodies and their uses
WO2007067991A3 (en) Human monoclonal antibodies to o8e
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
WO2005042029A3 (en) Psma formulations and uses thereof
MX358705B (es) Agentes de union de esclerostina.
PT2161336E (pt) Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
WO2008109533A3 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
WO2006039135A3 (en) Irta-4 antibodies and their uses
WO2005017112A3 (en) Methods of inhibiting cancer growth by binding to nuclear receptors
CY1114151T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα ως προς την κιναση τυροσινης πρωτεϊνης 7 (ρτκ7) και η χρηση αυτων
CY1113958T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε φουκοζυλ-gμ1 και μεθοδοι για τη χρηση αντι-φουκοζυλ-gμ1
HK1143739A (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application